Multiclass Primary Antiretroviral Drug Resistance in a Patient Presenting HIV-1/2 Dual Infection

Centers for Disease Control. Factsheet HIV Type 2. (Updated October 1998. Accessed 24 June 2010.) Available from http://wonder.cdc.gov/wonder/prevguid/m0038078/m0038078.asp.

Gottlieb G.S. , Eholié S.P. , Nkengasong J. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS 2008; 22: 2069–2072.

Soriano V. , Gomes P. , Heneine W. Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol 2000; 61: 111–116.

Barin F. , Cazein F. , Lot F. Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003–2006. AIDS 2007; 21: 2351–2353.

Benard A. , van Sighem A. , Taieb A. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2–infected patients: The ACHIEV2E Collaboration Study Group. Clin Infect Dis 2011; 52: 1257–1266.

Campbell-Yesufu O.T. , Gandhi R.T. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 2011; 52: 780–787.

Gilleece Y. , Chadwick D.R. , Breuer J. British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. HIV Med 2010; 11: 611–619.

Descamps D. , Damond F. , Matheron S. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004; 74: 197–201.

Gottlieb G.S. , Badiane N. , Hawes S. Emergence of multiclass drug resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource-limited West Africa. Clin Infect Dis 2009; 48: 476–483.

Gottlieb G.S. , Smith R. , Dia Badiane N. HIV-2 integrase variation in integrase inhibitor-naive adults in Senegal, West Africa. PLoS ONE 2011; 6: e22204.

Böni J. , Pyra H. , Schupbach J. Sensitive detection and quantification of particle-associated reverse transcriptase in plasma of HIV-1-infected individuals by the product-enhanced reverse transcriptase (PERT) assay. J Med Virol 1996; 49: 23–28.

Ntemgwa M.L. , d'Aquin T. , Brenner B. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother 2009; 53: 708–715.